Minutes of the 114th Joint Safety Review Meeting
Overview
At the joint meeting on October 23, 2026, participants reviewed suspected adverse reaction reports for COVID-19 and other vaccines, a draft amendment to the Enforcement Regulations of the Immunization Act, and the fiscal 2025 post-vaccination health survey. They found no major safety concerns for the vaccines reviewed and approved a draft ministerial ordinance amendment adding suspected Guillain-Barré syndrome after routine RSV vaccination to reportable events, with reports due within 28 days of vaccination.
Key points
- Based on suspected adverse reaction reports for COVID-19 vaccines, no major safety concerns were identified at this time.
- Based on reporting data, no major safety concerns were identified for vaccines other than COVID-19 vaccines.
- The meeting approved a draft ministerial ordinance amendment adding suspected Guillain-Barré syndrome after routine RSV vaccination to the reporting criteria.
- The results of the fiscal 2025 post-vaccination health survey were reported.
Overview
The meeting was held on October 23, 2026, as a joint session of the 114th Adverse Reaction Review Committee of the Health Science Council's Immunization and Vaccine Subcommittee and the 9th Safety Measures Investigation Council meeting of fiscal 2026.
The agenda covered reporting data for COVID-19 vaccines, the safety of other vaccines, and the draft ordinance amendment; results of the health survey were also reported under other business.
Impact
It was concluded that no major safety concerns were identified for COVID-19 vaccines, even after ongoing monitoring and deliberation.
It was concluded that suspected adverse reaction reports and other information raised no major safety concerns for vaccines other than COVID-19 vaccines. In assessments of suspected sequelae, ADEM, GBS, anaphylaxis, and deaths, reports included cases where a relationship was suggested and cases deemed unclear due to insufficient information.
The committee decided to proceed with the draft ordinance amendment as proposed. It was scheduled to be promulgated after the necessary procedures and to take effect on the date of promulgation.
Details
COVID-19 vaccine reports were tabulated for April 1 through June 30, 2026. For some products, the cumulative number of people eligible for vaccination could not be calculated because of returns and other factors, so reporting frequencies could not be shown. Overall, the reporting frequency for Meiji Seika Pharma products was one order of magnitude higher than for other companies. The period overlapped with the early post-marketing surveillance period, and the effect of intensive information collection was cited as an explanation.
For other vaccines, the cumulative number of people eligible for vaccination was about 1,000 for Gardasil, about 120,000 for Silgard, and about 160,000 for Abrysvo. The death report frequencies for five-component vaccines and Prevenar 20 were 0 to 0.14 and 0 to 0.18 per 100,000 vaccinations, respectively, both below the urgent review threshold of 0.5. For Abrysvo, manufacturers reported 31 cases and medical institutions reported 7 cases; fetal deaths accounted for 2 cases and 1 case, respectively, and causality assessments for all were gamma.
Cases reviewed by experts included 9 suspected sequelae, 1 suspected ADEM, 6 suspected GBS, and 21 suspected anaphylaxis cases. Death reports included cases from before, during, and after the target period; 15 cases had been reported through October 2, 2026, with 1 assessed as beta and 10 under investigation.
Public comments were solicited on the draft approved at the previous committee meeting, and no comments required changes to the draft. The reporting criteria in Article 5 of the Enforcement Regulations of the Immunization Act will add suspected Guillain-Barré syndrome after routine RSV vaccination and related vaccinations, with a reporting period of 28 days after vaccination.
The post-vaccination health survey is conducted under Article 47 of the Immunization Act to provide information on health status after vaccination, among other purposes. Since fiscal 2022, it has shifted from postcard to online surveys, leading to challenges such as fewer responses. The committee reported plans for the fiscal 2026 survey to reduce response burden through measures such as standardizing questions and to improve the response rate.